IDCommon TopicsL1DTopicsExamples
L2D120

(1.1)		T156 (9%): repeated_measures (100%)

T67 (8%): questionnaire (76%)

T14 (8%): scores (28%), score (20%), scale (16%)

T272 (7%): baseline (45%)

T23 (6%): pain (35%), symptoms (34%), severity (20%)

T241 (4%): randomized (50%)

T12 (4%)

T249 (3%): quality (54%), life (40%)

T367 (3%): measured (38%), effect (33%), effects (24%)
L1D415

(1.5)		T156 (23%): qol (3%), scales (3%), life_qol (2%), subscales (2%), internal_consistency (2%)

T67 (15%): items (6%), item (3%), questionnaire (3%)

T14 (10%): scale (12%), scores (9%), validity (9%), reliability (8%), measure (8%)

T23 (4%): symptoms (17%), symptom (14%), pain (13%)
  • Treatment decision intervention for prostate cancer patients
  • Buspirone treatment of dyspnea in outpatients receiving chemotherapy: A University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP) study.
  • A comparison of simple single-item measures and the NCI Common Toxicity Criteria version 3.0 measure of peripheral neuropathy.
  • Health preference instruments in a breast cancer population: Is there a ceiling effect when compared to the quality-of-life instruments?
  • Unmet needs in lung cancer: Preliminary data analysis of comparison between caregivers, oncologists, nurses, and patient’s perceptions from a national multicenter study (E-LUNG).
L1D563

(1.5)		T67 (42%): exercise (2%), depression (2%), physical_activity (2%), physical (1%), anxiety (1%)

T249 (5%): intervention (32%)

T156 (4%): qol (13%), life_qol (8%)
  • Effects of exercise on cancer-related biomarkers in breast cancer survivors: An updated systematic review and meta-analysis of randomized controlled trials.
  • Web-based stepped collaborative care intervention in the context of advanced cancer.
  • Long-term results of a phase II randomized controlled trial (RCT) of a psychological intervention (Conquer Fear) to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors.
  • The influence of Tai Chi (TC) and support therapy (ST) on fatigue and quality of life (QOL) in women with breast cancer (BC).
  • Improved coping to mediate the positive effects of integrated palliative care on quality of life and depression.
L1D584

(1.5)		T156 (30%): qol (6%), eortc_qlq-c30 (4%)

T14 (6%): scores (24%), score (16%)

T67 (5%): questionnaire (6%), physical (6%), questionnaires (5%), items (3%)

T241 (4%): arms (19%), arm (17%), randomized (17%)

T272 (4%): baseline (41%)

T23 (3%): symptoms (17%), pain (11%), deterioration (10%)
  • Effect of evening melatonin on the survival of patients with advanced non-small cell lung cancer (ANSCLC).
  • Minimally important differences on the functional assessment of cancer therapy-breast (FACT-B) scale: Results from ECOG study 1193
  • Quality of life values recover faster following high-dose chemotherapy (HDCT) compared to standard chemotherapy (CT) in patients (pts) with breast cancer (BC) (Meeting abstract).
  • Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel (Meeting abstract).
  • Quality of life (QOL) and psychosocial support in women with metastatic breast cancer (MBC): results of a multicentre randomized trial.
L1D614

(1.9)		T134 (54%): bone (4%), bone_metastases (4%), zoledronic_acid (3%), bone_resorption (2%)
  • A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM).
  • Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP).
  • A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer.
  • DOSE INTENSE THERAPY OF BONE METASTASES WITH PAMIDRONATE (Meeting abstract).
  • Zolendronic Acid in patients with Adenocarcinoma of the Prostate M1
L1D635

(1.5)		T38 (54%): weight (3%), bmi (3%), body_composition (2%), cachexia (2%), nutritional_status (2%)
  • The impact of less than 8% weight loss on overall survival in subjects with non-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024.
  • Metabolic syndrome and breast cancer: Effects of a 16-week combined exercise intervention.
  • Nutritional Assessment in Advanced Cancer (Meeting abstract).
  • Subgroup analyses of randomized phase II study on gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer.
  • Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
L1D687

(1.6)		T12 (28%): cipn (3%), chemotherapy-induced_peripheral (2%), neuropathy_cipn (2%), hands (2%), feet (1%)

T23 (4%): severity (18%), pain (16%)

T79 (4%): neuropathy (13%), peripheral_neuropathy (9%), neurotoxicity (7%)

T142 (3%): placebo (30%)

T181 (3%): skin (14%), topical (10%), cutaneous (9%)

T241 (3%): randomized (21%), arm (16%), arms (15%)

T28 (2%): daily (22%)

T283 (2%): side_effects (20%), severe (17%), side_effect (17%)

T355 (2%): incidence (24%), prevention (24%)
  • Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).
  • Severity of pain after unilateral and bilateral primary reconstruction with a tissue expander in breast carcinoma patients.
  • Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.
  • A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
  • A Phase III Double Blinded, Placebo Controlled, Randomized Trial of Gabapentin in Patients with Chemotherapy-Induced Peripheral Neuropathy: A North Central Cancer Treatment Group Study
L1D805

(1.4)		T40 (19%): approval (4%), fda (4%)

T228 (5%): drug (38%)

T93 (3%): approved (15%)

T65 (3%): ae (9%), aes (8%), sae (5%), saes (5%)

T251 (3%): design (26%)

T236 (3%): review (14%), reports (13%), reporting (10%), published (7%)

T292 (2%): trials (59%)

T29 (2%): maximum_tolerated (14%), mtd (12%), dlt (9%), dose_escalation (9%)

T11 (2%): supplemental_indications (2%), marketing (2%), notification (1%), biopharmaceutics (1%), budgeted (1%)

T395 (2%): phase (81%)

T258 (2%): clinical_trials (72%)

T240 (2%): safety (29%)

T239 (2%): new (35%)

T230 (1%): accrual (32%)
  • Validation of toxicity burden score for use in phase I clinical trials.
  • Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience.
  • Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities.
  • Economic growth of BRIC nations and access to early-phase oncology clinical trials: An overview.
  • Pulmonary function tests (PFT) results in a phase 1 (Ph1) oncology patient (pt) population.
L2D121

(1.4)		T11 (17%): online (30%), experts (25%), professional (19%)

T127 (11%): physicians (12%), oncologists (9%), barriers (6%), providers (6%)

T78 (7%): survey (34%), education (20%)

T96 (6%): participation (9%), issues (8%), how (7%), needs (6%), participate (6%)

T125 (6%): process (25%)

T40 (5%): funding (23%), investigators (19%), conduct (13%), approval (13%), committee (13%)
L1D416

(1.5)		T127 (19%): services (3%), out-of-pocket_costs (2%), health_care (2%), out-of-pocket (2%), transportation (2%)

T84 (9%): costs (9%), cost (8%)

T16 (8%): medicare-age (1%), tl1tr00098 (1%), societal’s (1%), pwy (1%), callbacks (1%)

T33 (5%): insurance (6%)

T31 (4%): access (12%), program (9%), coverage (7%)

T72 (4%): hospital (10%), center (7%), denied (5%)

T343 (4%): care (23%)
  • Clinical trials networks and enrollment of historically underrepresented populations in medical oncology trials.
  • Disparities in access to dental care appointments among head and neck cancer patients.
  • Patient out-of-pocket and insurer payment decisions for bevacizumab for metastatic colorectal cancer: A Canadian analysis.
  • Doing better with less: Can a quality improvement intervention to increase adherence to evidence-based cancer screening guidelines reduce health care costs?
  • How to cut cost in oncology: a pilot study (Meeting abstract).
L1D451

(1.5)		T78 (33%): preferences (2%), survey (2%), asked (2%), respondents (1%), satisfaction (1%)

T96 (13%): participate (7%), felt (4%)

T215 (8%): decision (8%), decision_making (6%), preference (4%)
  • What do 676 primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a German survey of the northeastern German Society of Gynecological Oncology (NOGGO).
  • Factors that influence patient satisfaction in colorectal cancer patients
  • A Decision Analysis on the Balance Between Cancer Survival and Cisplatin Ototoxicity in Children with Germ Cell Tumors
  • 1998 Pediatric Oncology Group (POG) Growth Factor (GF) Survey: Utilization Patterns and Comparisons with the American Society of Clinical Oncology (ASCO) Surveys (Meeting abstract).
  • Attitudes about chemotherapy for Japanese patients with or without cancer: Doctors, nurses, and the general public.
L1D460

(1.9)		T11 (25%): researchers (1%), initiative (1%), partnership (1%), implement (1%), staff (1%)

T125 (12%): process (4%), created (3%)

T31 (6%): research (11%), access (7%), project (6%)

T127 (6%): community (6%), providers (6%), resources (3%)

T40 (5%): requirements (4%), launched (4%), collaboration (3%), scientific (3%), investigators (2%)
  • Implementation of the California Oncology Emergency Preparedness Plan (COEPP): Updated results of an ASCO-supported state oncology society (SOS) project for patient (PT) protection.
  • Duke University Global Cancer Program: A multidisciplinary approach to partnerships in global cancer care.
  • The Quality of an Oncologist’s Life - the view of psychodynamic psychology
  • Computer-assisted outreach by patient care navigators using laptop wireless communication.
  • Translational Breast Cancer Research Consortium (TBCRC) Patient Advocate Working Group (PAWG): An approach to research advocacy.
L1D493

(1.7)		T78 (30%): survey (3%), respondents (2%), education (2%)

T11 (12%): training (2%), researchers (1%)

T96 (11%): participants (4%), participation (4%), felt (3%), knowledge (3%), issues (3%)
  • The (Evolving) Role of Tumor Board in Patient Care at A Community Hospital (Meeting abstract).
  • Evaluating a new income source for medical oncologists: Market research.
  • Quality improvement: An assessment of participation of medical oncologists.
  • The practice patterns and outlook of gynecology oncologists in the treatment of pediatric, adolescent and young adults with gynecologic malignancies: A survey study.
  • Pediatric sibling donor bone marrow transplant: Assessing distress in donors and family members.
L1D582

(1.7)		T11 (24%): training (2%), learning (1%), didactic (1%), skills (1%), curriculum (1%)

T78 (16%): communication (3%), education (3%), survey (2%), educational (2%), surveys (2%)

T96 (8%): knowledge (6%), issues (6%)

T127 (7%): teaching (4%), team (4%), physicians (3%), nurse (3%), health_care (3%)
  • Necessity for including quality of life diagnostics and therapy in routine oncological care: Evaluation by methods of clinical guideline implementation.
  • Home-care for cancer patients: results after a 3.5 years' experience
  • The effects of a required end-of-life care and pain management teaching session
  • Assisting cancer patients with pervasive technologies
  • IVR-based cancer symptom assessment: Nurses’ expectations and perceived barriers.
L1D607

(1.4)		T12 (10%): pain_management (5%), opioids (4%)

T67 (9%): questionnaires (4%), questionnaire (3%)

T78 (7%): education (3%), survey (3%), telephone (3%), questions (3%), communication (2%)

T13 (6%): silverware (0%), shouldn´t (0%), nurse-reported (0%), governement (0%), item-test (0%)

T23 (5%): pain (27%)

T127 (5%): nurses (8%), nurse (6%)

T96 (4%): felt (5%), clinic (4%), addiction (3%), issues (3%), take (2%)

T343 (3%): care (12%), visit (10%), visits (10%), adherence (10%), clinic_visits (8%)

T249 (3%): life (28%), quality (20%), intervention (18%)
  • Interactive Audiovisual vs Standard Telephone Communication Between Oncologists and Home of Patients Undergoing Out-Patient Chemotherapy. The Marilin (Multicenter Audio-Video Regional Interactive Linkage Investigation) Randomized Trial.
  • Interest of systematic patient contact by phone call between two cycles of chemotherapy.
  • Patterns of management of rash associated with epidermal growth factor receptor inhibitors (EGFRIs): A national practice survey.
  • Identifying best support care patients in an outpatient medical oncology unity: difficulties presented by training medical oncologists.
  • Implementation of adherence to erlotinib by a treatment-monitoring program.
L1D626

(1.6)		T11 (24%): topics (1%), websites (1%), google (1%), experts (1%), organizations (1%)

T222 (7%): guidelines (9%), recommendations (7%), guideline (5%), consensus (5%)

T78 (6%): internet (3%), survey (3%), newspapers (2%)

T125 (6%): content (7%), process (5%)

T127 (4%): oncologists (8%), physicians (5%)

T96 (4%): how (6%), knowledge (6%), mentioned (3%), words (3%)
  • Care delivery barriers to personalized medicine in breast cancer.
  • Chemotherapy error: analysis of an error reporting database, recent case reports, error reduction methods, current reporting systems
  • Assessment of personhood indicators for instrument development for persons with primary brain tumors.
  • Relative importance of oncologist access and patient pre-selection in limiting the uptake of companion diagnostic tests for solid cancers in the United States.
  • "Printcracy" vs. "Printoritarism": An Ethical Debate About the Press Impact in Cancer.
L1D676

(1.7)		T40 (25%): investigators (3%), sponsor (3%), portfolio (2%), industry (2%), conduct (2%)

T11 (16%): infrastructure (1%), workload (1%), personnel (1%), staffing (1%), ncccp (1%)

T125 (5%): process (9%), processes (5%)

T31 (5%): research (22%)
  • Lessons from the other side of clinical trial accrual: Screen failures at the Josephine Ford Cancer Center/Henry Ford Health System in 2010.
  • Development of Web-Based Systems to Facilitate Phase III Clinical Trials Enrollment: Early Results from the CTSU Pilot Project.
  • Evaluation of an oncology cooperative group audit preparation workshop.
  • An analysis of clinical trials in clinicaltrials.gov to assess the scope of NCI support and inclusion on NCI’s cancer.gov website.
  • Improving the efficiency and effectiveness of clinical research regulatory review processes: Lessons from the Six Sigma Body of Knowledge.
L1D718

(1.5)		T127 (17%): physicians (3%), physician (3%), orders (3%), practices (3%), qopi (2%)

T11 (15%): staff (3%), feedback (1%)

T125 (8%): process (8%), implemented (6%), errors (5%)

T222 (8%): implementation (9%), practice (8%), guidelines (4%)

T343 (4%): care (26%), oncology (16%)
  • Using high performance thin layer chromatography as a post production quality control tool: should all samples be analyzed?
  • Effect of computerized physician order entry (CPOE) on chemotherapy prescribing error.
  • Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service.
  • The Quality Oncology Practice Initiative (QOPI): Understanding and Improving “Best Practices” by a Community of Oncologists
  • Oncology care for rural Kansans via telemedicine: the establishment of a teleoncology practice (Meeting abstract).
L1D721

(1.5)		T53 (32%): rcts (4%), articles (4%), abstracts (4%), publication (3%), journals (2%)

T236 (10%): published (20%), reporting (11%)

T40 (7%): investigators (5%), industry (5%), journal (5%), sponsorship (3%), funding (3%)

T292 (4%): trials (42%)
  • Is quality of life (QOL) a prognostic factor in ovarian cancer?
  • Trends in head and neck squamous cell carcinoma (HNSCC) clinical research as reported in the ASCO Proceedings from 1996- 2006.
  • The importance of beta, type II error, in negative trials in oncology (Meeting abstract).
  • Quality of reporting of phase II trials in oncology in highly ranked oncology journals.
  • Cancer clinical trial acronyms presented at ASCO Annual Meetings.
L1D773

(1.5)		T84 (22%): costs (6%), cost (5%)

T13 (7%): distributor (0%), bortezomib+thalidomide (0%), 486-587m (0%), linkable (0%), leftovers (0%)

T58 (6%): pharmacy (5%), claims (4%), medicare (4%), claims_data (3%), supply (3%)

T127 (5%): reimbursement (4%), prescribing (4%), healthcare (2%), paid (2%), payment (2%)

T40 (5%): fda (7%), manufacturer (4%)

T228 (5%): drug (34%), drugs (33%)
  • Three years of reimbursement decisions regarding novel oncology drugs in Israel: A retrospective evaluation of correspondence with the ESMO Magnitude of Clinical Benefit Scale.
  • Cytogenetic and fluorescence in situ hybridization testing in veterans with chronic lymphocytic leukemia.
  • Retrospective review of steroid-induced acne in patients with breast cancer.
  • Understanding thalidomide-associated deep vein thrombosis/pulmonary emboli (DVT/PE): Comparison of quality and information included in adverse event reports from clinical trials, clinical practice, STEPS, and the medical literature.
  • The cost of treating pancreatic cancer: A pilot study.
L2D124

(1.1)		T30 (6%): bevacizumab (73%)

T58 (4%): real-world (47%)

T153 (3%): first-line (54%), second-line (33%)

T291 (3%): treatment (46%), therapy (43%)

T128 (3%): docetaxel (43%), paclitaxel (29%)

T312 (2%): line (36%), lines (34%), st_line (30%)

T305 (2%): vs (50%)

T210 (2%): receiving (53%)

T295 (2%): regimens (54%), regimen (43%)

T285 (2%): calculated (48%), estimated (35%)

T170 (2%): compared (41%), than (27%)

T332 (2%): or (26%), this (16%), for (15%)

T396 (2%): conclusions (36%), background (35%), methods (29%)

T65 (2%): hypertension (46%), aes (31%)

T228 (2%): agents (30%), drugs (24%), drug (19%)

T390 (2%): total (70%)

T229 (2%): duration (49%), cumulative (25%)

T175 (2%): mbc (32%), anthracycline (27%), taxane (19%)

T93 (2%): therapies (60%), approved (37%)

T404 (2%): months (100%)

T398 (2%): chemotherapy (95%)

T387 (1%): respectively (47%), similar (34%)
L1D419

(1.5)		T18 (10%): advanced_nsclc (11%)

T128 (5%): platinum (14%), carboplatin (11%), vinorelbine (8%), docetaxel (8%), paclitaxel (8%)

T153 (4%): second-line (21%), pfs (19%), first-line (18%)

T353 (4%): ps (36%), performance_status (22%)

T275 (3%): nsclc (52%)

T111 (2%): pemetrexed (29%)

T197 (2%): response_rate (28%), second_line (20%)

T274 (2%): kaplan-meier_method (11%), log-rank_test (7%), cox_proportional (7%), cox_regression (6%), log-rank (6%)

T294 (2%): group (20%), between (17%), better (14%), groups (14%), two_groups (11%)

T376 (2%): os (52%), overall_survival (45%)

T166 (2%): cisplatin (40%)

T244 (2%): prognostic_factors (31%), multivariate_analysis (24%)

T305 (2%): vs (35%), longer (18%)

T356 (2%): survival (81%)

T132 (1%): gefitinib (15%), erlotinib (14%)

T332 (1%): or (16%), as (14%), with (12%), in (9%), to (9%)

T295 (1%): regimens (40%), regimen (28%)

T88 (1%): objective_response (22%)

T223 (1%): retrospective_analysis (15%), we_retrospectively (15%), retrospectively (12%), retrospective (10%)
  • Retrospective analysis on the factors related with lower response rates to second-line chemotherapy after failure of adjuvant/front-line chemotherapy for colorectal cancer.
  • Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience.
  • The clinicopathologic features and clinical outcomes of gastric cancer (GC) initially presented with disseminated intravascular coagulopathy (DIC)
  • Retrospective multicenter cohort of nab-paclitaxel plus gemcitabine (NG) after FOLFIRINOX failure in advanced pancreatic cancer (APC): Effectiveness, tolerability, and response markers.
  • Comparative effectiveness of regimens of first-line platinum-based chemotherapy for advanced lung squamous cell carcinoma.
L1D557

(1.7)		T37 (50%): cardiac (5%), lvef (5%), ejection_fraction (5%), left_ventricular (4%), cardiotoxicity (4%)

T160 (4%): trastuzumab (26%)
  • Evaluation of pretransplant variables predicting cardiomyopathy following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation.
  • Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.
  • Frequency of cardiovascular events in patients with metastatic renal cell carcinoma under sunitinib treatment.
  • Acute heart failure in bone marrow transplantation: Impact of intravenous immune globulin as adjuvant therapy.
  • Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.
L1D610

(1.7)		T84 (53%): costs (5%), cost (4%), cost-effectiveness (3%)
  • Cost-effectiveness of capecitabine in combination with oxaliplatin (XELOX) compared with FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation.
  • Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS).
  • Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer.
  • Evaluation of cost-effectiveness of early KRAS testing in high-risk recurrence colorectal cancer patients in Italy.
  • Cost-effectiveness (CE) analysis of CHOP and rituximab for diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC).
L1D636

(1.6)		T58 (39%): claims (4%), claim (3%), index_date (3%), real-world (2%), health_plan (2%)

T84 (4%): costs (22%), cost (14%)

T341 (2%): diagnosis (40%), database (29%)

T135 (2%): adjusted (11%), retrospective_cohort (9%), unadjusted (6%)

T116 (2%): inpatient (24%), outpatient (18%), hospitalizations (12%)
  • Costs and resource utilization associated with skeletal related events in Medicare patients with prostate cancer metastatic to bones.
  • Treatment patterns among elderly follicular lymphoma patients diagnosed between 2000 and 2011: An analysis of linked SEER-Medicare data.
  • What are the resource implications of palliative chemotherapy for ovarian cancer? (Meeting abstract).
  • Fractures and health care resource use in cancer patients with chemotherapy-associated peripheral neuropathy (CAPN).
  • Retrospective claims database cost analysis of second-line sorafenib (SR) or sunitinib (SR) therapy in treatment of patients (pts) with renal cell carcinoma (RCC).
L1D655

(1.4)		T30 (21%): mcrc (8%), bevacizumab (5%), metastatic_colorectal (4%)

T312 (4%): line (12%), st_line (12%), lines (11%), nd_line (9%), 1st_line (6%)

T85 (4%): oxaliplatin (21%), capecitabine (15%), irinotecan (11%)

T153 (3%): first-line (23%), pfs (21%), progression_free (12%)

T376 (2%): overall_survival (54%), os (43%)

T353 (2%): ecog (25%), ps (24%), ecog_ps (18%)

T10 (2%): 5-fu (13%), 5fu (9%)

T107 (2%): bleeding (13%)

T295 (2%): regimen (41%), regimens (39%)

T212 (1%): records (11%), cancer_agency (8%), reviewed (8%), retrospective_chart (6%), pharmacy_database (6%)

T65 (1%): aes (11%), proteinuria (10%), htn (9%), hypertension (8%)

T291 (1%): therapy (40%), treatment (40%)

T296 (1%): crc (39%), colorectal_cancer (22%)

T274 (1%): kaplan-meier_method (11%), cox_regression (9%), survival_curves (7%), kaplan-meier (6%), kaplan_meier (6%)

T93 (1%): ocs (16%), approved (13%), therapies (10%)

T304 (1%): outcomes (48%)

T15 (1%): elderly (34%), age (25%)
  • Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
  • The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS).
  • High- versus low-dose leucovorin in the FOLFOX regimen for metastatic colorectal cancer (mCRC).
  • Real-world treatment patterns and outcomes associated with bevacizumab (bev) in metastatic colorectal cancer (mCRC).
  • An Australian single institution experience in treating primary glioblastoma multiforme from 2010-2012.
L2D126

(1.3)		T341 (4%): diagnosis (37%), diagnosed (27%)

T35 (3%): 5-year (27%), median_follow-up (22%)

T212 (3%): presentation (28%), reviewed (17%)

T141 (3%): resection (41%), surgical_resection (26%)

T346 (3%): surgery (55%)

T274 (3%): kaplan-meier_method (17%), kaplan-meier (13%), log-rank_test (10%)

T317 (3%): histology (53%)

T103 (2%)

T152 (2%): localized (32%)

T231 (2%): patients (25%), all (21%), there (18%), only (15%)

T43 (2%): cases (39%), rare (20%)

T244 (2%): multivariate_analysis (28%), prognostic_factors (27%)

T294 (2%): between (39%), group (25%)

T388 (2%): years (66%)

T376 (2%): overall_survival (58%), os (41%)

T15 (2%): age (51%)

T356 (2%): survival (96%)

T370 (2%): stage (83%)

T213 (2%): prognosis (26%), poor (19%)

T73 (2%): seer_database (59%)

T143 (2%): tumor_size (48%)
L1D421

(1.5)		T212 (5%): presentation (11%), reviewed (7%), records (6%)

T309 (4%): adenocarcinoma (26%), squamous_cell (17%)

T43 (4%): cases (22%)

T341 (3%): diagnosis (40%), diagnosed (25%)

T205 (3%): stomach (12%), gastric_cancer (9%), gastric (7%)

T3 (3%): turkey (4%), country (3%), world (3%), latin_america (3%), india (3%)

T317 (3%): histology (16%), stage_iv (15%), large_cell (10%), poorly_differentiated (10%)

T124 (3%): head (6%), neck (6%), larynx (5%), oral_cavity (3%)

T19 (3%): unknown_primary (7%), well_differentiated (4%), neuroendocrine (4%)

T72 (2%): hospital (14%), epidemiological (9%)

T89 (2%): smokers (10%), smoking (10%), non-smokers (7%), tobacco (6%)

T275 (2%): small_cell (34%), lung_cancer (26%)

T355 (2%): incidence (52%)

T46 (2%): epscc (3%), bronchoscopy (2%), incidental (2%), tuberculosis (2%), anorectal (2%)

T306 (2%): male (23%), males (22%), female (21%), females (20%)

T223 (2%): retrospective (15%), between_january (13%), our_institution (8%)

T235 (2%): metastasis (15%), histological (8%)

T394 (2%): carcinoma (64%)

T231 (1%): patients (22%), only (17%), all (16%), limited (14%), there (12%)

T316 (1%): stage_iii (24%), stage_ii (22%)
  • Differences Between Synchronous and Metachronous Multiple Primary Neoplasms. (Meeting abstract).
  • Factors related to the prognosis of colorectal cancer
  • Prognostic factors in lung cancer patients. Population based study.
  • Female patients with soft tissue sarcoma are at a higher risk for developing breast cancer.
  • Incidental vs. clinical diagnosis of renal cell carcinoma (RCC): Population, treatment and outcome in a cohort of 828 patients followed at Instituto Oncológico Henry Moore (IOHM).
L1D486

(1.7)		T103 (40%): seminoma (4%), germ_cell (3%), nsgct (3%), testicular (3%), bep (3%)

T171 (5%): relapse (23%), relapsed (19%), salvage (16%), relapses (12%)

T344 (3%): died (23%), are_alive (19%), ned (12%)

T35 (3%): median_follow-up (29%)
  • Routine outpatient (OP) review following treatment for Hodgkin's disease (HD): is it an efficient way of detecting relapse? (Meeting abstract).
  • Survival, surgical resectability, and late effects in the hepatoblastoma patients treated by cisplatin plus pirarubicin (CITA) chemotherapy.
  • Residual tumor resections (RTR) in patients with germ cell tumors (GCT) after salvage chemotherapy.
  • Improving the Outcome of Salvage Treatment for Relapsed Non Seminomatous Germ Cell Tumours (NSGCT) (Meeting abstract).
  • Long term outcome of salvage therapy for unselected patients with non-seminomatous germ cell testicular tumors (GCT). Spanish Germ Cell Cancer Group Experience.
L1D523

(1.6)		T157 (29%): soft_tissue (4%), sarcoma (3%), sts (3%), extremity (3%), sarcomas (2%)

T152 (7%): local (12%), localized (10%), local_recurrence (9%), local_control (8%), margins (6%)

T35 (5%): median_follow-up (15%)

T141 (3%): resection (11%), preoperative (6%)

T244 (3%): prognostic_factors (30%), multivariate_analysis (15%)

T346 (3%): surgery (41%)

T171 (2%): efs (25%)
  • Ewing tumor of bone - updated report of the European Intergroup Cooperative Ewing's Sarcoma Study EICESS 92
  • Tumor size as prognostic factor in osteosarcomas.
  • Neo-adjuvant chemotherapy for primary high grade extremity soft tissue sarcoma: A matched case control study
  • Primary Breast Sarcoma: a Historical Clinico-Pathologic Review.
  • Role of radiotherapy to primary/metastatic sites in pediatric patients with metastatic rhabdomyosarcoma in the BERNIE study.
L1D658

(1.6)		T73 (24%): race (6%), surveillance_epidemiology (6%), seer_database (5%), seer (4%)

T33 (10%): disparities (3%), ses (3%), marital_status (2%), population-based (2%), socioeconomic_status (2%)

T274 (4%): cox_proportional (14%)

T341 (4%): diagnosed (33%), diagnosis (28%)

T135 (3%): more_likely (12%), trends (9%), adjusted (8%), demographic (7%), age_gender (6%)

T15 (3%): age (37%), younger (20%)

T170 (3%): compared (25%), than (19%), distribution (14%)

T306 (2%): females (25%), males (22%), gender (20%)
  • Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.
  • Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.
  • Ampulla of Vater adenocarcinoma in the Veteran's Affairs population.
  • Clinicopathologic features and survival outcomes of secondary diffuse large b-cell lymphoma after a primary solid malignancy: SEER propensity-matched analysis.
  • Survival of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and peripheral T-cell lymphoma (PTCL): A propensity matched analysis of the Surveillance, Epidemiology and End Results (SEER) database.
L1D808

(1.5)		T274 (6%): cox_proportional (12%), propensity_score (6%)

T141 (6%): resection (13%), surgical_resection (8%), resected (7%)

T135 (5%): adjusted (7%), more_likely (7%), age_sex (7%), demographic (5%), age_gender (5%)

T33 (4%): ncdb (9%), receipt (5%)

T76 (4%): after_adjusting (8%), variables (7%), multivariable_analysis (6%), multivariate (5%), worse (5%)

T143 (4%): lymph_nodes (9%), lymph_node (9%), tumor_size (8%), ln (7%), nodal (5%)

T316 (3%): stage_ii (24%), stage_iii (21%)

T348 (3%): hr_ci (36%), hr (29%)

T25 (2%): staging (8%), pathologic (7%), n2 (6%), t4 (6%), t-stage (4%)

T346 (2%): surgery (38%)

T341 (2%): diagnosed (26%), registry (21%), data_base (19%), database (17%)

T15 (2%): age (32%), younger (18%), elderly (17%), older (16%)

T73 (2%): surveillance_epidemiology (14%), race (12%), seer_database (9%)

T370 (2%): stage (72%)

T376 (2%): overall_survival (59%), os (39%)

T72 (2%): national (27%), queried (13%)
  • Outcome of Patients Receiving Radiation Therapy (RT) for Stage I-III Non Small-Cell Lung Cancer (NSCLC): Results of the 1995-1997 Patterns of Care Study (PCS) in Japan.
  • Impact of wait times on survival of women with uterine cancer.
  • Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with ≥ pT3 and/or pN+ bladder cancer (BCa).
  • Retrospective study of treatment and outcome for muscle-invasive bladder cancer (MIBC) in Kentucky.
  • Differences in survival between symptomatic versus asymptomatic recurrence following cystectomy for bladder cancer.
L2D131

(1.1)		T38 (5%): bmi (54%), body_mass (46%)

T246 (5%): risk (48%), risk_factors (27%)

T121 (5%): infection (100%)

T355 (4%): incidence (56%)

T212 (4%): medical_records (23%), reviewed (22%), records (22%), charts (12%)

T223 (3%): retrospective (36%)

T15 (3%): age (67%)

T341 (3%): diagnosis (43%), diagnosed (30%)

T260 (2%): use (81%)

T186 (2%): kg (100%)

T349 (2%): who (50%), had (42%)

T135 (2%): logistic_regression (32%), odds_ratio (28%)

T332 (2%): or (29%)

T179 (2%): complications (52%), complication (30%)

T231 (2%): without (37%), patients (31%)

T109 (2%): mortality (100%)

T198 (2%): among (33%), type (32%)
L1D426

(1.6)		T134 (56%): bone (5%), bone_metastases (3%), zoledronic_acid (3%), sre (3%), sres (3%)
  • Incidence and risk factors of bisphosphonate associated osteonecrosis of the jaws.
  • Preventing skeletal related events in veterans on bisphosphonates for bone metastases.
  • Self assessment of buccodental toxicity: Comparison of patients with metastatic renal cell carcinoma (RCC) treated with sunitinib with patients treated with chemotherapy.
  • An overview of in-patient pamidronate use in an inner-city urban hospital
  • Incidence of bone fracture in Japanese patients receiving long-term hormone therapy for prostate cancer.
L1D473

(1.3)		T188 (5%): hb (5%), dl (5%), 10g_dl (4%), blood_transfusion (4%), hb_dl (4%)

T13 (5%): lfm (0%), 5-pregnenetriol (0%), record-based (0%), icesp (0%), erythropoëtine (0%)

T3 (4%): france (5%), world (3%), italy (3%), per_capita (3%), country (3%)

T224 (3%): dose_reduction (14%), dose_reductions (9%), diarrhea (8%)

T39 (3%): anemia (20%), febrile_neutropenia (14%), neutropenia (12%)

T260 (3%): management (9%), use (8%), clinical_practice (6%), need (6%), observational_study (6%)

T324 (2%): toxicity (44%), toxicities (27%)

T48 (2%): japan (7%), december (6%), october (6%), ineligibility (6%), registered (5%)

T212 (2%): records (14%), reviewed (10%)

T128 (1%): carboplatin (17%), vinorelbine (11%)

T12 (1%): self-questionnaire (4%), candy (4%), opioid (3%), opioids (3%), pain_relief (2%)

T283 (1%): side_effects (19%), severe (17%), gastrointestinal (12%), tolerate (11%), adverse_effects (10%)

T355 (1%): incidence (38%)

T127 (1%): oncologists (7%), physicians (5%), record_forms (3%)

T102 (1%): even_when (7%)

T72 (1%): centre (9%), patient_demographics (7%), center (7%)

T353 (1%): ps (38%), performance_status (24%)

T322 (1%): reasons (24%), reason (18%)

T343 (1%): oncology (23%), supportive_care (13%)

T187 (1%): most (41%), majority (22%)

T311 (1%): because (15%), usually (10%)

T398 (1%): chemotherapy (81%)

T295 (1%): regimens (25%), regimen (24%)

T390 (1%): due (23%), total (20%), life_expectancy (17%), per_patient (12%)

T15 (1%): years_old (24%), elderly (23%), age (22%)

T124 (1%): head (13%), neck (9%)

T291 (1%): treatment (67%)

T290 (1%): given (35%), administered (19%)
  • Nursing Support Program to Decrease or Prevent Side Effects of Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent Epithelial Ovarian Cancer (REOC)
  • Sub-optimal treatment is a contributory factor to poor UK survival rates in non-small cell lung cancer
  • Impact of capecitabine-related toxicities on chemotherapeutic dose delivery in colorectal cancer.
  • Clinical outcomes of breast cancer patients with hepatitis C: A case series
  • Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population.
L1D604

(1.5)		T121 (38%): fn (6%), fever (4%), infection (4%)

T39 (5%): febrile_neutropenia (35%), neutropenia (35%)

T186 (4%): anc (25%), absolute_neutrophil (13%)

T116 (3%): hospitalization (23%)

T99 (2%): nhl (15%), non-hodgkin_lymphoma (10%)
  • Efficacy and safety of balugrastim in chemotherapy-induced neutropenia: Integrated analysis of two randomized phase III studies.
  • Performance of MASCC score and other factors for identifying low-risk febrile-neutropenic cancer patients.
  • Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
  • Outpatient single dose ceftriaxone and amikacin vs. imipenem/cilastatin monotherapy in the empiric treatment of pediatric patients with high risk fever aneutropenia. A randomized, prospective clinical trial.
  • Frequency of neutropenia-related events during chemotherapy and the use of pegfilgrastim and filgrastim in community practice: results of the ACCEPT study
L1D621

(1.5)		T121 (10%): fn (9%), pegfilgrastim (6%), neutropenic_complications (5%)

T39 (6%): febrile_neutropenia (30%), neutropenia (19%)

T186 (5%): anc (11%), absolute_neutrophil (10%), nadir (6%)

T295 (5%): dose_intensity (34%), regimen (21%), regimens (20%), rdi (18%)

T202 (3%): ac (24%)

T224 (3%): dose_reductions (36%), dose_reduction (34%)

T38 (3%): obese (11%), bmi (10%), body_mass (7%), index_bmi (6%), obesity (6%)

T290 (3%): delays (51%)

T158 (2%): cyclophosphamide (26%), dose_dense (15%), doxorubicin (15%)

T345 (2%): adjuvant_chemotherapy (43%), adjuvant (43%)

T60 (2%): cmf (19%), caf (15%)

T212 (2%): charts (12%), reviewed (9%), retrospective_review (7%)

T286 (2%): cycles (82%)

T222 (2%): practice (9%), esbc (9%)

T194 (2%): dose (70%)

T259 (2%): experienced (36%), occurred (29%)
  • Febrile neutropenia and reduced dose intensity in patients with aggressive non-Hodgkin’s lymphoma (NHL) treated with CHOP and CNOP.
  • How accurate is clinician reporting of chemotherapy side effects? A prospective study comparing clinician with patient-reported symptoms.
  • Patient self-initiated antibiotic therapy for fever during neoadjuvant and adjuvant breast cancer chemotherapy.
  • Prophylactic ciprofloxacin to prevent febrile neutropenia in adjuvant breast cancer patients receiving docetaxel (nonanthracycline) regimens.
  • Project ChemoInsight Reveals Physician Practice Patterns for Adjuvant Breast Cancer Chemotherapy, and Compares the Dose Intensity of CMF, AC, and CAF. (Meeting abstract).
L1D637

(1.4)		T38 (35%): bmi (5%), body_mass (5%), obesity (4%), index_bmi (3%), obese (3%)

T64 (3%): vitamin (5%), intake (3%), hdl_cholesterol (3%), lipid_profile (2%)

T195 (3%): childhood (16%), survivors (12%)

T246 (2%): risk (34%), dm (22%), increased_risk (22%)

T135 (2%): adjusted (12%), age_gender (12%)

T76 (2%): after_adjusting (15%)

T73 (2%): race (18%)

T0 (2%): osteoasarcoma (0%), dr09-0719 (0%), insulin-users (0%), allohsct_survivors (0%), ‘incident’ (0%)
  • Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer.
  • Doxazosin use in prostate cancer patients: Its effect on development of metastases.
  • The effect of rapamycin on PSA kinetics in men without prostate cancer.
  • Predictors of Bone Mineral Density in Pediatric Cancer Survivors
  • Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia.
L1D702

(1.7)		T105 (47%): pregnancy (5%), pregnancies (4%), during_pregnancy (3%)

T103 (3%): gonadal (5%), dysgerminoma (5%), gestational_trophoblastic (4%), testicular (4%), gonadotropin (3%)
  • Testicular sperm extraction and hCG-based hormonal treatment in cancer survivors with postchemotherapy azoospermia.
  • Assessment of breast cancer risk factors in asymptomatic hospital staff women aged 32 to 59: A descriptive report.
  • Synchronous and metachronous malignant tumors.
  • Pregnancy (PG) in the patient with lymphoma does not predict an adverse prognosis
  • Fertility of females after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
L1D723

(1.5)		T107 (57%): vte (6%), venous_thromboembolism (4%), thrombosis (4%), pulmonary_embolism (3%)
  • Differences in the clinical presentation, severity, and treatment outcome for symptomatic versus asymptomatic pulmonary embolism in cancer patients.
  • Serum erythropoietin (sEPO) testing and treatment patterns for transfusion-dependent (TD) patients (pts) with myelodysplastic syndromes (MDS).
  • Effect of anticoagulation after inferior vena cava filter placement in gynecologic oncology patients on survival.
  • Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study.
  • Venothromboembolism (VTE) in patients (pts) with acute myelogenous leukemia (AML).
L1D781

(1.4)		T150 (12%): comorbidities (7%), comorbidity (5%)

T38 (7%): bmi (8%), body_mass (6%), diabetes (4%), index_bmi (4%)

T141 (7%): preoperative (8%), partial_nephrectomy (5%), postoperative (5%), postoperative_complications (4%), perioperative (4%)

T183 (4%): chronic_kidney (8%), gfr (8%), ckd (7%), renal (6%), renal_function (5%)

T179 (3%): complications (13%), hospital_stay (9%)

T76 (3%): variables (11%), multivariate_analyses (7%)

T13 (3%): h-bmi (0%), non-dad (0%), iss-stages (0%), 84m (0%), nckuh (0%)

T15 (3%): age (34%), older (27%), elderly (20%)

T135 (3%): logistic_regression (12%)

T51 (2%): mm (8%), multiple_myeloma (6%)

T274 (2%): cox_regression (13%), cox_proportional (12%), kaplan-meier (7%)

T244 (2%): multivariate_analysis (24%), univariate_analysis (23%)
  • SOLITARY BONE PLASMACYTOMA: OUTCOME AND PROGNOSTIC FACTORS FOLLOWING RADIOTHERAPY (Meeting abstract).
  • Less co-morbidity in elderly cancer patients undergoing chemotherapy or radiotherapy (Meeting abstract).
  • Comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
  • Potential life years lost due to Colorectal Cancer (CRC)
  • Oncologic kidney surgery in obese patients.
L1D850

(1.5)		T58 (12%): incident (5%), claims (3%), medicare (3%), index_date (3%)

T109 (8%): mortality (8%), statins (7%), statin_use (5%), all-cause_mortality (5%)

T135 (5%): adjusted (17%)

T37 (5%): congestive_heart (5%), cardiovascular (4%), cardiac (4%), myocardial_infarction (4%), ischemic_heart (4%)

T38 (4%): diabetes (13%), statin (8%)

T341 (4%): diagnosed (28%), diagnosis (28%), database (17%)

T246 (4%): risk (35%), increased_risk (23%)

T274 (4%): cox_proportional (18%), adjusted_hazard (10%)

T33 (3%): population-based (6%), administrative_databases (4%), large_population-based (3%), population-based_cohort (3%)

T348 (3%): hr_ci (41%), hr (23%)
  • Surveillance of drug treatments in cancer patients by database linkage.
  • Cardiotoxicity of tyrosine kinase inhibitors among veterans diagnosed with renal cell carcinoma.
  • HMG CoA reductase inhibitors and the risk of colorectal cancer.
  • Impact of beta blocker medication on survival outcome of ovarian cancer: A nationwide population-based cohort study.
  • Diabetes in elderly patients with breast cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database.
L2D147

(1.2)		T116 (15%): length (100%)

T67 (12%): depression (46%)

T23 (6%): pain (41%), symptoms (35%), severity (24%)

T343 (5%): care (29%), interventions (25%), medical (20%)

T14 (4%): score (39%), scores (32%), measures (21%)

T135 (4%): logistic_regression (26%), more_likely (17%), demographic (16%)

T72 (3%): hospital (43%), center (32%)

T150 (3%): functional_status (59%), comorbidities (41%)
L1D448

(1.7)		T116 (32%): length (4%), hospitalization (4%), nationwide_inpatient (4%), in-hospital_mortality (3%), hospitalizations (3%)

T33 (7%): adjusted_odds (3%), medicaid (3%), disparities (3%), population-based (3%), income (2%)

T135 (4%): logistic_regression (8%), odds (8%), retrospective_cohort (7%), multivariate_logistic (6%), more_likely (5%)

T58 (4%): codes (7%), medicare (6%)

T179 (3%): complications (19%), hospital_stay (9%)

T84 (3%): cost (16%), costs (14%), charges (11%)
  • Thirty-day readmissions in metastatic cancer patients: Room for improvement?
  • Increasing risk for venous thromboembolism among hospitalized cancer patients.
  • Clostridium difficile infection among children with cancer.
  • Epidemiology and Outcomes of Serious Influenza Infections in Lung Cancer Patients
  • The health economic cost of squamous cell cancer of the head and neck in the elderly
L1D525

(1.6)		T67 (23%): psychosocial (2%), questionnaire (2%), physical (2%), emotional (2%), depression (2%)

T195 (14%): survivors (18%)

T173 (6%): impaired (6%), difficulties (5%), strength (4%), impairment (4%), impairments (4%)

T78 (5%): parents (6%), survey (5%), education (3%), respondents (3%)

T156 (4%): functioning (10%), qol (9%), life_qol (9%)
  • Working ability and educational level among long-term survivors of testicular cancer (TCSS) compared to a general population (GenPop).
  • Insomnia symptoms and memory problems in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study.
  • Oral health-related quality of life among children undergoing cancer therapy.
  • Hope and distress to predict patient-centered outcomes among adolescent and young adult patients with cancer.
  • Prevalence of memory problems that limit daily functioning in adult cancer patients: A national representative sample of the U.S. population.
L1D570

(1.5)		T156 (26%): qol (6%), functional_assessment (4%), life_qol (4%)

T67 (22%): physical (3%), assessment_scale (2%), symptom_burden (2%)

T14 (6%): scores (20%), score (12%), scale (11%)
  • Quality of life outcomes of advanced colorectal cancer in an integrative treatment setting: The Cancer Treatment Centers of America experience.
  • The changes in quality of life during the palliative chemotherapy for solid cancer.
  • Fatigue in advanced cancer: a study on the different dimensions and their correlates.
  • Age-dependent effects of intensive chemotherapy (IC) on quality of life (QOL) and physical function in patients with acute myeloid leukemia (AML).
  • Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study.
L1D630

(1.6)		T67 (15%): physical (2%), questionnaires (2%), symptom_burden (2%), questionnaire (2%), psychological (2%)

T156 (11%): qol (7%), life_qol (6%), qol_scores (4%)

T124 (9%): neck (6%), swallowing (6%), head (5%), hnc (4%), oral_cavity (3%)

T23 (5%): pain (13%), symptoms (12%), dry_mouth (10%)

T14 (4%): scores (20%), score (15%), scale (14%)

T141 (3%): postoperative (7%), postoperatively (7%), post-op (6%), preoperative (5%), chemo-radiation_therapy (4%)

T159 (3%): dysphagia (12%), concurrent (6%)

T0 (3%): reflux (1%)
  • Effects of animal-assisted visits on quality of life during multi-modal radiation therapy: Chemotherapy regimens.
  • Quality of life in patients with rectal carcinoma: comparison between pre- vs post-operative chemoradiotherapy (CT-RT) (Meeting abstract).
  • Long-term complications following axillary lymph node dissection (ALND) (Meeting abstract).
  • Longitudinal study of arm impairments, function and quality of life following mastectomy.
  • Patient-reported outcomes following preoperative chemoradiotherapy for rectal cancer: A prospective multicenter observational study.
L1D670

(1.6)		T67 (26%): assessment_scale (4%), edmonton_symptom (4%), depression (3%), anxiety (3%), depression_anxiety (2%)

T23 (15%): pain (17%), symptoms (13%), symptom (10%)

T12 (14%): drowsiness (7%), opioids (4%), opioid (3%)
  • Retrospective Review of Slow Release Oral Narcotic Use in Terminally Ill Cancer Patients (Meeting abstract).
  • Sleep disturbance in patients with advanced cancer: Frequency and factors associated with response to specialist-based outpatient supportive care.
  • A survey on insomnia in patients with non-small cell lung cancer (NSCLC).
  • PREDICTIVE SCALE FOR PAIN RELIEF IN PATIENTS (PTS) WITH CANCER PAIN (Meeting abstract).
  • Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening.
L1D671

(1.6)		T150 (49%): daily_living (4%), cga (3%), comprehensive_geriatric (3%), iadl (3%), adl (3%)

T173 (6%): activities (11%), cognition (8%), cognitive_impairment (7%), mmse (7%)
  • Comprehensive Geriatric Assessment (CGA): Reliable tool for tailored oncologic treatment.
  • Gender differences in comprehensive geriatric assessment (CGA): Results from the IN-GHO registry.
  • Comprehensive geriatric assessment (CGA) in elderly women with early breast cancer.
  • The relationship among age, anxiety, and depression in older adults with cancer.
  • Integrating a touchscreen-based brief geriatric assessment in older adults with multiple myeloma.
L1D683

(1.4)		T116 (25%): admitted (7%), admission (6%)

T121 (4%): infection (10%), fever (9%), sepsis (7%)

T179 (3%): complications (18%)

T343 (3%): care (18%), medical_oncology (12%)

T12 (3%): analgesics (4%), sedation (4%), opioids (3%), cid (2%), neuroleptics (2%)

T127 (3%): team (5%), service (5%), consultation (4%), nursing (4%), services (4%)

T23 (3%): pain (19%), symptoms (17%)

T72 (3%): hospital (26%)

T212 (2%): reviewed (14%)
  • Severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer: A cost of illness analysis.
  • Palliative Care of Terminally Ill Cancer Patient (Pt) in Italy: is Too Much Always Better?
  • Cancer patients in US nursing homes: quality of end of life care
  • Predicting imminent death in acutely ill cancer patients with dyspnea (Meeting abstract).
  • Cisplatin (CDDP) substitution for carboplatin (CBDCA): an easily occurring, but preventable fatal error (Meeting abstract).
L1D707

(1.4)		T71 (14%): prediction_model (5%), validation (4%), validate (4%), validated (4%), performance (3%)

T116 (10%): admitted (7%), admission (5%), icu (4%), intensive_care (4%), emergency_center (4%)

T101 (5%): prediction (17%), predict (14%), predicting (14%), predictive (14%), predicted (11%)

T76 (5%): variables (17%), predictors (11%)

T121 (3%): fn (8%), mascc (6%), fever (6%), respiratory_failure (5%), prophylaxis (4%)

T196 (3%): model (62%)

T139 (2%): receiver_operating (18%), specificity (14%), characteristic_curve (11%), sensitivity (9%)

T135 (2%): logistic_regression (25%)

T186 (2%): platelets (9%), platelet_count (8%), count (7%), absolute_neutrophil (7%), wbc (6%)

T188 (2%): dl (13%), hemoglobin (8%), hb (8%)

T244 (2%): prognostic (21%), multivariate_analysis (18%), univariate_analysis (15%)
  • Risk models for neutropenic complications associated with breast cancer adjuvant chemotherapy.
  • Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study.
  • Factors associated with mortality in an inpatient acute palliative care unit at a comprehensive cancer center.
  • Novel algorithms to predict the occurrence of in-hospital venous thromboembolism in cancer patients: Machine learning classifiers developed from the 2012 national inpatient sample.
  • Hemoglobin concentration before chemotherapy is an independent prognostic factor in ovarian carcinomas
L1D728

(1.5)		T116 (36%): hospice (6%), palliative_care (4%), icu (3%)

T127 (10%): services (7%), service (5%), referral (4%), health_care (4%)

T72 (5%): hospital (23%)
  • Inpatient care directed by hospitalists vs. oncologists: Comparison of patient satisfaction and outcomes.
  • Prevalence and estimated trend in chemotherapy use near death from population-based studies on cancer patients: A systematic review and meta-analysis.
  • Quality indicators for end-of-life breast cancer care: Testing the use of administrative databases.
  • Seasonal mortality in terminally ill cancer patients.
  • Benefits of physician orders for scope of treatment (POST) forms on end-of-life care in cancer patients: Insights from the West Virginia registry.
L1D771

(1.6)		T109 (17%): cumulative_incidence (7%), general_population (4%), mortality (4%), cardiovascular_disease (4%)

T195 (13%): survivors (17%), childhood (14%)

T246 (6%): risk (28%), increased_risk (22%)

T37 (5%): cardiac (12%), heart (8%)

T351 (3%): ci (33%), rr_ci (25%), rr (19%)

T33 (3%): chronic_conditions (5%), national_health (3%), population-based (3%), log-binomial_regression (3%)

T341 (3%): diagnosis (37%), diagnosed (36%)
  • Cardiovascular mortality (CVM) among testicular nonseminoma (TN) survivors after chemotherapy (CHEM) or surgery (SURG).
  • Diabetes risk in childhood cancer survivors: A population-based study.
  • Increasing risk of chronic health conditions in aging survivors of childhood cancer:  A report from the Childhood Cancer Survivor Study.
  • Solid organ transplant after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study.
  • Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.
L2D151

(1.2)		T12 (13%)

T14 (5%): score (61%)

T156 (4%): qol (100%)

T23 (4%)

T272 (4%): baseline (60%)

T249 (3%): life (49%), quality (47%)

T283 (3%): severe (70%)

T142 (3%)

T325 (2%): over (48%)

T164 (2%): weeks (52%), week (48%)

T302 (2%): mean (67%)

T28 (2%): daily (100%)

T315 (2%): no (36%), study (36%)

T241 (2%): randomized (90%)
L1D459

(1.8)		T12 (48%): opioid (4%), opioids (3%), fentanyl (3%), analgesia (2%), morphine (2%)

T142 (3%): placebo (19%), double-blind (18%)
  • Efficacy and safety of intranasal ketamine for the management of breakthrough pain in chronic pain. A randomized, double-blind, placebo-controlled, cross-over trial.
  • A randomized comparison of oral methadone as a "first-switch" opioid versus opioid switching between sustained-release morphine and oxycodone for oncology outpatients with pain management problems.
  • Exploration of pain management following implementation of WHO pain guidelines.
  • Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain.
  • COMPARISON OF ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) AND STANDARD THERAPY FOR CONTROL OF PERSISTENT CANCER PAIN (Meeting abstract).
L1D608

(1.7)		T84 (33%): costs (7%), cost (7%)

T121 (10%): fn (7%), prophylaxis (5%)

T285 (4%): estimated (15%), threshold (11%), estimate (10%)

T116 (4%): hospitalization (14%), inpatient (8%)
  • A Belgian Model Comparing Filgrastim Use in Adjuvant CMF as Secondary Prophylaxis Versus Filgrastim Administration Only to Patients at Risk for Hospitalisation Due To Febrile Neutropenia: Morbidity and Cost Implications. (Meeting abstract).
  • Pharmacoeconomic study in head and neck cancer patients: Impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs.
  • Risk and outcomes of chemotherapy (chemo)-induced thrombocytopenia (TCP) in solid tumor patients (Meeting abstract).
  • Assessing a prognostic model for predicting VTE occurrence in cancer patients.
  • Cost and Outcomes of Mucositis Prophylaxis Among Patients Receiving 5-Fluorouracil (5FU).
L1D640

(1.6)		T134 (24%): bone_metastases (8%), bone_pain (7%), painful_bone (5%)

T12 (17%): pain_relief (9%), brief_pain (5%), analgesics (5%)

T23 (4%): pain (54%)

T14 (2%): score (25%), scale (24%), scores (16%)

T95 (2%): ra-223 (11%), crpc (6%), nilsson (6%), dichloride (6%), radium (5%)

T45 (2%): prostate_cancer (31%)
  • A retrospective analysis of palliative MRgFUS treatment bone metastases from renal cell carcinoma (RCC).
  • Adjuvant analgesic therapy for cancer-related pain: Does the evidence support the practice?
  • Gabapentin (G) in Neuropathic Cancer Pain (NCP) (Preliminary Report).
  • Use of thermal sensation as a biomarker of response to palliative radiotherapy for cancer-induced bone pain.
  • Management of cancer-related vertebral compression fracture: Comparison of treatment options: A literature meta-analysis.
L1D657

(1.6)		T124 (17%): swallowing (6%), head (5%), hnc (5%), neck (5%)

T156 (14%): qol (7%), eortc_qlq-c30 (4%)

T159 (6%): crt (12%), dysphagia (10%)

T67 (5%): eating (5%), questionnaires (5%), self-reported (3%)

T14 (5%): scores (20%), scale (15%), score (10%)

T23 (4%): symptoms (10%), dry_mouth (10%), pain (7%), symptom (6%), deterioration (6%)
  • A feasibility study of dynasplint to prevent trismus in head and neck cancer patients receiving radiation therapy.
  • Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study.
  • Comparison of patient performance between PEG/no PEG placement in head and neck cancer patients during chemoradiotherapy treatment.
  • Functional morbidities in patients > 65 years compared with younger patients undergoing organ preservation therapy (OPT) for squamous cell carcinoma (SCC) of larynx (L) or propharynx (OP).
  • Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971.
L1D661

(1.7)		T67 (16%): acupuncture (2%), antidepressants (2%), facit-f (2%), sham_acupuncture (1%), symptom_inventory (1%)

T57 (9%): hot_flashes (16%)

T142 (7%): placebo (19%)

T23 (6%): severity (15%), symptoms (12%), symptom (8%)

T12 (5%): hot_flash (14%)

T164 (4%): weeks (34%), week (28%)

T241 (4%): randomized (32%), arms (17%)
  • PSYCHOLOGICAL AND PSYCHOSOCIAL OUTCOMES OF ORAL CLONIDINE IN POSTMENOPAUSAL BREAST CANCER PATIENTS (PTS) WITH TAMOXIFEN-INDUCED HOT FLASHES (HF): A URCC CCOP STUDY (Meeting abstract).
  • Patient controlled methylphenidate (PCM) for cancer related fatigue (CRF): A preliminary report
  • Fluoxetine Versus Placebo in Advanced Cancer Outpatients: a Placebo-Controlled, Double-Masked Trial of the Hoosier Oncology Group.
  • Acupuncture for hot flashes for prostate cancer patients.
  • Internet based double-blind cross-over clinical trial to test efficacy of high dose isoflavone soy in controlling breast cancer survivor hot flashes.
L1D679

(1.6)		T45 (19%): prostate_cancer (11%), radical_prostatectomy (6%)

T156 (14%): qol (6%), life_qol (6%), physical_function (5%), fact-p (4%), bowel_function (3%)

T67 (11%): sexual_function (10%), sexual (6%)

T173 (4%): urinary_incontinence (14%)

T14 (4%): scores (18%), score (14%)
  • Comparative Study of the Clinical Efficacy of 500 mg qD vs 250 mg tid Dosing of Flutamide in Metastatic Prostate Cancer.
  • Physical Function is Better Maintained in Elderly than in Younger Women during Adjuvant Chemotherapy for Breast Cancer.
  • Recovery of quality of life (QOL) and physical function over three years in adult survivors of acute myeloid leukemia (AML) after intensive chemotherapy (IC) compared with normative data.
  • Disruptions in activities of daily living for African American prostate cancer patients compared to Whites.
  • Association between baseline physical function and comorbidity status with patient-reported quality of life after prostate cancer treatments: Combined analysis of two prospective cohort studies.
L1D693

(1.7)		T136 (54%): antiemetic (6%), cinv (3%), emesis (3%), antiemetics (3%)
  • Electronic medical record (EMR) order sets, counseling, and complementary therapy for chemotherapy induced nausea/vomiting (CINV) control.
  • Concordance between substance P levels and antiemetic guidelines.
  • Level of scientific evidence underlying palliative care recommendations arising from the National Comprehensive Cancer Network (NCCN) clinical practice guidelines.
  • Prognostic variables of chemotherapy-related anticipatory nausea and vomiting: a univariate and multivariate analysis (Meeting abstract).
  • Chemotherapy induced nausea and vomiting in breast cancer treated with antiemetic prophylaxis as recommended by the ASCO antiemesis guidelines.
L1D751

(1.6)		T124 (12%): head (9%), neck (7%)

T159 (8%): gy (9%), rtog (5%), rtog_criteria (5%), dysphagia (5%)

T12 (6%): mouthwash (3%), severe_om (3%), salivary_flow (3%), pain_relief (2%), pilocarpine (2%)

T310 (4%): rt (29%), radiation (17%), radiotherapy (15%)

T241 (4%): randomized (26%), arm (16%), arms (15%)

T146 (3%): oral_mucositis (36%)

T28 (3%): oral (27%), daily (17%)

T13 (3%): mukhopadhyay (1%), polymyxin-tobramycin-amphotericin (1%), ncic-ctcae (1%), emitters (1%), exact-test (1%)

T142 (3%): placebo (36%)

T133 (2%): primary_endpoint (22%), secondary_endpoint (12%)

T355 (2%): om (27%), incidence (23%), prevention (20%)
  • Poly TLR agonist polyantigenic vaccine (Mycobacterium w) in palliative therapy of head and neck cancer.
  • Long-term follow-up of low-dose isotretinoin (13-cRA) versus beta carotene to prevent oral carcinogenesis (Meeting abstract).
  • Phase III quality of life (Qol) study: reduction in hyposalivation does not improve Qol for head and neck (H&N) cancer patients post radiation therapy (P-RT). RTOG 9709
  • Licorice in prevention of radiation induced mucositis.
  • A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer.
L1D796

(1.8)		T188 (58%): dl (4%), transfusion (4%), esa (4%), hb (4%), hb_dl (3%)
  • Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors: Pronost study.
  • Dosing and outcomes study of erythropoiesis-stimulating therapies - D.O.S.E.
  • Case Controlled Retrospective Study of Anemia Treatment in Cancer Patients Receiving Recombinant Human Erythropoietin (EPO) and Intravenous Iron Dextran (INFeD[trade] (FE)) (Meeting abstract).
  • Transfusion trends in chemotherapy-induced anemia: Observation from the Medicare 5% Sample, 1992-2005.
  • Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy-induced anemia
L2D153

(1.2)		T33 (14%): receipt (49%), population-based (26%)

T78 (8%): survey (43%)

T127 (6%): health_care (25%), physician (15%)

T343 (4%): care (41%)

T135 (3%): more_likely (40%), likelihood (21%), demographic (21%)

T96 (3%): how (18%), participants (13%), personal (10%), participation (9%)

T72 (3%): national (36%), hospital (27%)

T98 (2%): sample (28%)

T73 (2%): asian (100%)

T15 (2%): age (44%)

T215 (2%): decision (28%), least (15%)

T386 (2%): women (74%)
L1D462

(1.5)		T78 (31%): survey (3%), surveyed (2%), education (2%)

T215 (9%): decision (8%), decision-making (7%), decisions (5%), decision_making (4%)

T96 (8%): knowledge (6%), how (4%), information_about (4%), participate (4%), participants (3%)

T127 (5%): physicians (10%), physician (8%), oncologists (6%)
  • Cancer patients’ trade-offs for efficacy, toxicity, and cost.
  • Knowledge of cancer clinical trials in a population being screened for cancer.
  • Ethnic disparities in the impact of breast cancer on the workforce: A pilot study.
  • What's in a name: Describing ductal carcinoma in situ (DCIS).
  • Voice analysis during bad news discussion in oncology: Decreased speaking rate, pitch, and nonverbal communication of empathy.
L1D511

(1.5)		T33 (33%): insurance (3%), income (2%), less_likely (2%), insurance_status (2%), disparities (2%)

T73 (8%): race (10%)

T135 (6%): more_likely (11%), demographic (6%)

T72 (4%): national (14%), united_states (7%), hospital (7%)
  • Racial differences in attitudes toward molecular testing for personalized cancer therapy.
  • Place matters: Identifying communities with unequal risk for prostate cancer.
  • Identification of risk factors leading to a late stage diagnosis in elderly melanoma patients.
  • Breast cancer survival in developing countries: The remainder disparities in health services access.
  • Patient-reported sources of breast cancer survivorship care four years after diagnosis.
L1D609

(1.8)		T84 (51%): costs (4%), cost (3%), cost-effectiveness (3%), cost-effective (3%), qaly (2%)
  • The lifetime costs of breast cancer therapy in Canada (Meeting abstract).
  • Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective.
  • Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer.
  • Laparoscopic treatment of endometrial cancer: A cost-effectiveness analysis.
  • Is cerebrospinal fluid cytology a useful test?
L1D672

(1.6)		T67 (25%): questionnaire (3%), anxiety (3%), distress (3%), depression (2%), psychological (2%)

T78 (20%): survey (2%), fear (2%), asked (2%), questions (1%), caregivers (1%)

T96 (9%): needs (6%), concerns (4%), participants (4%)
  • National study of patients, caregivers and physicians reveals pain associated with advanced prostate cancer as the primary concern.
  • Psychosocial impact of parental cancer on Moroccan children: Result of an exploratory study.
  • Follow-up care of breast cancer survivors: Survey of patients and analysis of treatment data in a German breast cancer centre.
  • Distress in cancer survivors attending a multidisciplinary survivorship clinic.
  • Young patients and gastrointestinal (GI) tract malignancies: Are we addressing the unmet needs?
L1D674

(1.5)		T67 (37%): depression (3%), anxiety (3%), psychological (2%), questionnaire (2%), distress (2%)

T156 (6%): life_qol (10%), qol (10%)

T78 (5%): survey (4%), education (4%), coping (3%), satisfaction (2%), perceived (2%)

T14 (4%): scores (23%), scale (15%), score (12%)
  • Falls, physical performance deficits, and functional losses in cancer survivors with chemotherapy-induced neuropathy (CIPN): A University of Rochester CCOP study.
  • Does the information level of cancer patients influence quality of life and psychologic adaptation to the disease? A prospective study (Meeting abstract).
  • The differences in sexual satisfaction, quality of life, and social support between patients with prostate cancer and cervical cancer after radiotherapy.
  • Long term peripheral neuropathy symptoms in breast cancer survivors.
  • A population-based study on the quality of life for cancer patients as reported in a tumor registry follow-up.
L1D678

(1.6)		T33 (21%): receipt (5%), less_likely (3%), disparities (3%)

T73 (8%): race (12%), surveillance_epidemiology (9%), white (7%)

T135 (5%): more_likely (11%), odds (9%), logistic_regression (9%), adjusted (6%), likelihood (6%)

T45 (5%): prostate_cancer (11%), localized_prostate (6%), radical_prostatectomy (6%)

T47 (4%): mastectomy (12%), breast_conserving (9%), bcs (8%), invasive_breast (6%)

T58 (4%): medicare (8%), medicare_claims (7%), seer_medicare (6%), incident (5%), utilization (5%)

T341 (3%): diagnosed (42%)

T15 (3%): age (37%), older (27%)
  • National population-based study of racial variation in characteristics and outcomes of young breast cancer patients: Analysis of temporal trends.
  • Prostate cancer management: Racial disparities in the United States.
  • Utilization of accelerated partial breast irradiation for ductal carcinoma in situ, 2002-2007: Report from the National Cancer Data Base.
  • Management trends in the United States for low-, intermediate-, and high-risk prostate cancer.
  • Prevalence and predictors of active surveillance management for black males diagnosed with low risk prostate cancer.
L1D743

(1.4)		T222 (14%): guidelines (7%), surgeons (4%)

T127 (11%): referral (4%), ontario (4%), medical_oncologist (3%), quality_indicators (3%), quality_measures (2%)

T72 (4%): referred (12%), hospitals (11%), national (7%), hospital (7%)

T11 (4%): initiative (3%), experts (2%)

T212 (3%): charts (13%), reviewed (10%), records (8%)

T343 (3%): care (39%)

T141 (3%): resection (11%), post-operative (5%)

T346 (2%): surgery (33%), surgical (21%)

T33 (2%): process-of-care (3%), registries (3%), urban (3%), administrative_databases (2%), centralization (2%)

T316 (2%): stage_ii (28%), stage_iii (24%)

T341 (2%): registry (31%), diagnosed (24%)

T296 (2%): colon_cancer (34%)
  • Adherence to NCCN survivorship guidelines in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
  • Discrepancies in treatment of osteosarcoma according to insurance coverage: A review of the National Cancer Data Base.
  • Impact of a simple intervention that improves colon cancer lymph node yield and assessement.
  • Process and outcome indicators for evaluation of surgical activity in a high-risk gastric cancer area.
  • A tracking and feedback registry to reduce disparities in breast cancer care.
L2D163

(1.3)		T78 (18%): survey (58%), education (39%)

T127 (8%): physicians (30%)

T96 (8%): participants (22%)

T64 (5%)

T33 (4%): less_likely (51%), income (49%)

T343 (4%): health (31%), medical (23%), care (21%)

T80 (4%): screening (64%)
L1D490

(1.5)		T78 (22%): survey (3%), education (3%), surveyed (2%)

T89 (11%): smoking (8%), smoking_cessation (8%), quit (6%), quit_smoking (5%), smoked (5%)

T33 (10%): income (5%)

T127 (5%): financial_burden (5%), financial (4%), barriers (3%), physician (3%), transportation (3%)

T67 (5%): self-reported (6%)
  • Association between chronic myeloid leukemia (CML) treatment responses and patient satisfaction, functioning, and quality of life (QOL): Patient survey results.
  • Cancer-related self-efficacy in African American prostate cancer patients compared to whites.
  • Understanding the role of ethnic status in Intensive Care Unit (ICU) deaths among advanced cancer patients.
  • Five-year trajectories of financial recovery in low-income breast cancer survivors.
  • The role of acculturation in end-of-life outcomes for Latino advanced cancer patients.
L1D528

(1.5)		T57 (34%): ai (6%), aromatase_inhibitors (6%), tamoxifen (5%), osteoporosis (5%), ais (5%)

T142 (8%): bone_mineral (12%), bmd (12%), density_bmd (9%), osteopenia (8%)

T134 (5%): bone (18%), calcium (12%)

T67 (3%): dyspareunia (4%), vaginal_dryness (3%), questionnaire (3%), lifestyle (3%), sedentary (2%)

T386 (3%): women (51%)
  • Impact of skeletal related events (SREs) on health-related quality of life (HRQoL) and healthcare resource utilization (HRU) in prostate cancer patients with bone metastases (BM).
  • Characteristics of bone mineral density at the time of diagnosis in postmenopausal breast cancer patients.
  • Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.
  • Falls and fractures during aromatase inhibitors (AI) therapy.
  • Dermatologic adverse events in breast cancer patients receiving endocrine therapies.
L1D575

(1.8)		T64 (39%): cam (6%), cam_use (5%)

T78 (18%): alternative_medicine (4%), massage (3%), survey (3%), education (2%)
  • Herbal supplements: Boon or bane for older cancer patients?
  • Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer (kConFab).
  • A pilot international survey of oncologists' opinions and self-reported practice patterns on complementary and alternative medicine.
  • Complementary medicine (CAM) use among women receiving chemotherapy for ovarian cancer and the potential for interactions with prescribed medication.
  • Complementary and alternative medicine (CAM) use among cancer patients in community oncology settings.
L1D583

(1.5)		T78 (12%): survey (4%), respondents (2%), education (2%), survivorship_care (2%)

T105 (12%): fertility (8%), fertility_preservation (7%), infertility (7%), reproductive (5%)

T127 (9%): physician (5%), physicians (5%), providers (3%), oncologist (3%), oncologists (3%)

T96 (6%): knowledge (5%), clinic (4%), issues (3%), counseling (3%), discussed (3%)

T195 (6%): survivors (13%), children (11%), late_effects (7%)

T11 (5%): working (2%), practitioners (2%), scp (2%), an_internet-based (1%)

T222 (4%): practice (9%), guidelines (7%)
  • Fertility preservation: Are we telling patients what they want to know?
  • Randomized trial assessing the impact of survivorship care plans on the quality of care for childhood cancer survivors.
  • Diagnostic and treatment challenges of adolescent and young adult oncology patients.
  • Delay in conventional breast cancer treatment associated with alternative therapy usage.
  • The importance of fertility preservation in women with early breast cancer.
L1D590

(1.6)		T80 (17%): screening (13%)

T11 (9%): trained (1%), patient_navigators (1%), edifice_survey (1%), organizations (1%), suits (1%)

T127 (8%): barriers (7%), community (6%), representative_sample (4%)

T78 (8%): awareness (4%), education (3%), survey (2%)

T96 (6%): participation (6%), knowledge (6%), society (3%), participants (3%)

T33 (4%): urban (5%), insurance (3%), rural (2%)
  • Delays in breast cancer presentation and diagnosis in Nigeria.
  • Cancer antigen 125 (CA125) and the law of unintended consequences.
  • Performance of Complete Diagnostic Evaluation After an Abnormal Fecal Occult Blood Test Result.
  • Breast cancer screening controversy: Impact on other cancer screening programs.
  • Breast cancer wait times: Use of breast screening clinics affect presenting stage.
L1D647

(1.7)		T78 (38%): survey (2%), respondents (1%), asked (1%), want (1%), discuss (1%)

T96 (11%): family_members (4%), discussion (3%), know (3%), informed (3%), what (3%)

T102 (6%): they (11%), them (7%), regarding (6%)
  • Advanced cancer patients' self-reported perception of timeliness of their referral to outpatient supportive/palliative care and their survival data.
  • How to better help cancer patients face their coming death?
  • Discussing end-of-life treatment options: advanced cancer vs. amyotrophic lateral sclerosis
  • Perceptions of clinical trial participation in African American cancer patients.
  • What information do patients need about their disease or treatments and what they want for end of life?
L1D764

(1.6)		T64 (18%): intake (3%), consumption (3%), protective_effect (2%), vitamin (2%), dietary (2%)

T38 (10%): bmi (10%), body_mass (9%)

T246 (6%): risk (27%), risk_factors (16%)

T89 (5%): smoking (12%), alcohol_consumption (9%), alcohol (7%)

T57 (3%): postmenopausal_women (13%), hormone (10%), menopause (8%), postmenopausal (7%), estrogen (7%)

T135 (3%): adjusted (14%), non-users (9%)

T109 (3%): statin_use (7%), conditional_logistic (6%), during_person-years (5%), p-trend (5%), statins (5%)

T337 (3%): association_between (34%), association (19%)
  • Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.
  • A randomized trial of selenium and vitamin E for primary prevention of non-melanoma skin cancer: Trial results and experience from a low-resource setting.
  • Impact of aspirin use on the incidence of head and neck cancers: A systematic review and meta-analysis.
  • Influence of age on breast cancer risk in women living in the Altay Territory.
  • Association between use of non-steroidal anti-inflammatory drugs (NSAIDs) and statins and the risk of cutaneous melanoma (CM): A case-control study.
L1D804

(1.5)		T58 (16%): medicare (6%), claims (5%), utilization (4%)

T33 (11%): medicaid (2%), preventive_services (2%), receipt (2%), county (1%), task_force (1%)

T127 (8%): services (3%), health_care (3%), service (2%), provider (2%)

T80 (5%): screening (9%), annual (6%), colonoscopy (5%)

T31 (3%): access (12%), states (8%), program (7%), coverage (6%)

T325 (3%): period (19%), over (14%), substantial (11%), increasing (9%)

T84 (3%): costs (17%), cost (9%)

T45 (3%): prostate_cancer (20%)
  • Impact of early prostate cancer diagnosis in the United States.
  • Changes in androgen deprivation therapy overuse: Reimbursement response and characteristics of persistent overusers.
  • Cost-sharing and financial burden for Medicare patients with newly diagnosed cancer.
  • Medicare cancer screening in the context of clinical guidelines: 2000-2012.
  • Out-of-pocket cost trends for Medicare patients with newly diagnosed cancer.
L2D186

(1.1)		T292 (5%): trials (92%)

T376 (4%): os (52%), overall_survival (48%)

T351 (4%): ci (78%)

T285 (4%): estimate (36%), calculated (32%), estimated (31%)

T153 (3%): pfs (40%), first-line (32%)

T363 (3%): inclusion_criteria (28%), excluded (21%), met (18%), table (17%), criteria (17%)

T348 (3%): hr (44%), hazard_ratio (31%), hr_ci (25%)

T236 (3%): published (95%)

T291 (3%): treatment (46%), therapy (32%)

T332 (2%): or (28%)

T336 (2%): benefit (61%)

T396 (2%): background (36%), conclusions (35%), methods (29%)

T92 (2%): variation (100%)

T403 (2%): data (88%)

T248 (2%): from (39%), not (30%)

T305 (2%): vs (34%), longer (28%), versus (18%)

T398 (2%): chemotherapy (83%)

T375 (2%): included (71%)
L1D585

(1.7)		T53 (24%): meta-analysis (12%)

T141 (4%): postoperative (7%), resection (6%), curative_resection (5%), resected (5%), resectable (4%)

T292 (4%): trials (42%)

T348 (3%): hr_ci (26%), hr (25%), hazard_ratios (17%)

T336 (3%): benefit (40%), comparing (26%)

T92 (3%): individual_patient (30%), heterogeneity (28%)

T35 (3%): disease-free_survival (20%), dfs (18%)

T376 (3%): overall_survival (55%), os (41%)

T241 (2%): randomized (37%)

T351 (2%): ci (37%), confidence_interval (20%)
  • Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (R0) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis.
  • Neoadjuvant chemotherapy followed by radiotherapy for locally advanced cervix cancer: a meta-analysis using individual patient data from randomised controlled trials (RCTs)
  • A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer (NSCLC).
  • Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer.
  • A systematic analysis of high-dose radiation in the treatment of surgically unresectable, locally advanced non-small cell lung cancer.
L1D623

(1.6)		T53 (40%): meta-analysis (6%), rcts (4%), systematic_review (3%), randomized_controlled (3%)

T236 (6%): published (16%), search (10%), review (10%), reporting (9%)

T292 (4%): trials (35%), pooled (20%)
  • Erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa (EPO): A meta-analysis using the International Working Group criteria (IWGc) for MDS response.
  • New aromatase inhibitors (Als) as ist-line endocrine therapy (ET) in metastatic breast cancer (MBC): A pooled analysis of 3238 women from 8 phase III trials
  • Prophylactic cranial irradiation (PCI) and consolidation thoracic radiotherapy (TRT) for extensive stage small cell lung cancer (ES-SCLC): A systematic review and meta-analysis.
  • Does quality of treatment-related harms reporting affect conclusions about superiority of treatment?
  • Efficacy of docetaxel in metastatic, castration-resistant prostate cancer (mCRPC): Comparison with therapeutic standards in other solid tumors.
L1D730

(1.5)		T10 (27%): 5-fu (3%), circadian (3%), 5fu (2%), chronotherapy (2%), leucovorin (2%)

T30 (8%): metastatic_colorectal (9%), folfox (7%), mcrc (6%)

T241 (3%): randomized (17%), arms (16%), phase_iii (13%), arm (12%), randomization (11%)

T292 (3%): trials (27%)

T3 (2%): france (8%), north_america (7%), international (6%), north_american (6%), european (6%)

T0 (2%): q2wks+irinotecan (1%), 5fu+lv+ (1%), c1348 (1%), q1min (1%), dermathologic (1%)

T85 (2%): oxaliplatin (33%), irinotecan (24%)

T296 (2%): colorectal_cancer (26%), colon_cancer (17%), crc (15%), iii_colon (14%)

T336 (2%): benefit (20%), superior (13%)

T86 (1%): statistical_power (8%), power (8%), 60-day_all-cause (7%), 2-sided (5%)
  • Can Kampo medicine prolong the life of metastatic colorectal cancer (MCRC) patients with chemotherapy?
  • Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2,751 patients
  • Is the Continual Reassessment Method superior to the standard 3+3 dose escalation scheme?
  • Chronomodulated 48 hours infusion schedule (FLOX1) changes therapeutic index of oxaliplatin (OHP), 5-Fluorouracil (5-FU) regimen (FOLFOX4) in metastatic colorectal cancer patients: preliminary results of a multicentric phase II study (FLOX-1)
  • ACTIVITY CIRCADIAN RHYTHM AS AN INDEPENDENT PROGNOSTIC FACTOR OF SURVIVAL IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCC) (Meeting abstract).
L1D735

(1.5)		T160 (14%): her2 (11%), trastuzumab (8%)

T175 (10%): mbc (27%)

T57 (6%): endocrine_therapy (8%), et (6%), fulvestrant (5%), exemestane (4%), hormone_receptor-positive (4%)

T312 (5%): lines (18%), line (17%), st_line (10%)

T60 (4%): hr+ (10%), hormone_receptor (10%), er (10%)

T153 (2%): pfs (21%), first-line (17%), progression_free (11%)

T138 (2%): triple_negative (15%), tnbc (10%)

T362 (2%): breast_cancer (73%)

T384 (2%): metastatic (95%)

T345 (2%): adjuvant (31%), dfi (26%)

T291 (2%): therapy (58%), treatment (36%)
  • Real-world symptom burden and early treatment discontinuation in first-line metastatic breast cancer (MBC).
  • registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC).
  • Comparison of neoadjuvant anti-HER2 therapy for breast cancer in public versus private health care: Time to shorten the distance.
  • Potential life years saved using ado-trastuzumab emtansine (T-DM1) in second-line HER2-positive metastatic breast cancer.
  • Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.
L1D779

(1.6)		T150 (38%): daily_living (4%), iadl (4%), cga (4%), geriatric (3%), adl (3%)

T15 (4%): elderly (51%)

T324 (3%): toxicity (54%)

T173 (3%): activities (28%)

T353 (2%): ps (28%), performance_status (18%), ecog_ps (15%)

T39 (2%): febrile_neutropenia (8%), every_21d (6%), anemia (6%), adequate_renal (5%), neutropenia (5%)
  • Multidimensional Geriatric Assessment (MGA) Predicts Feasibility of Standard Carboplatin (Cb)-Cyclophosphamide (Cy) in Women over 70 with Advanced Ovarian Carcinoma (AOC): a GINECO Study.
  • Diffuse large B-cell non-Hodgkin’s lymphoma in the vulnerable/frail elderly. A multicentric randomized phase II trial from the GOELAMS/LYSA group.
  • Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).
  • Bevacizumab plus chemotherapy as first-line therapy for elderly patients with metastatic colorectal cancer: Interim results of the noninterventional CASSIOPEE study.
  • Preservation of Activities Daily Living (ADL) in a phase-II impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients 70 and older: The GERICO-01 Study by the French FNCLCC Group.
L1D790

(1.5)		T53 (22%): meta-analysis (5%), surrogacy (3%)

T292 (4%): trials (33%), pooled (19%)

T285 (4%): estimated (14%), estimate (11%), estimates (9%), calculated (7%)

T278 (4%): correlation_between (13%), as_surrogate (13%), correlation (11%)

T348 (3%): hazard_ratios (22%), hazard_ratio (22%), hr (21%)

T153 (3%): pfs (41%)

T196 (3%): weighted (22%), model (15%)

T92 (3%): heterogeneity (27%)

T236 (2%): published (21%)

T320 (2%): linear_regression (16%), coefficient (15%), relationship_between (15%), surrogate (14%)
  • The relationship between statins and breast cancer prognosis varies by statin type and exposure time: A meta-analysis.
  • Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
  • Progression-free survival (PFS) and overall survival (OS) in phase III trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
  • A model assessing how variable timing of outcome assessments impacts progression-free survival (PFS).
  • Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts).
L1D803

(1.6)		T33 (18%): receipt (7%), less_likely (4%)

T135 (7%): more_likely (11%), multivariate_logistic (6%), retrospective_cohort (6%), demographic (6%), logistic_regression (6%)

T58 (6%): medicare (8%), seer-medicare_database (6%), utilization (5%), medicare_claims (4%)

T341 (5%): diagnosed (35%), diagnosis (23%)

T15 (4%): age (32%), older (24%), elderly (17%)

T73 (3%): race (12%), surveillance_epidemiology (11%), black (8%), seer (7%)

T150 (3%): comorbidity (18%), charlson_comorbidity (11%), comorbidities (10%)

T127 (3%): ontario (5%), community (3%), medical_oncologist (3%), saw (3%), consultation (3%)

T198 (2%): among (39%), those_who (23%), those (22%)
  • Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) in colorectal cancer: A population-based analysis of adherence and non-receipt.
  • Receipt of chemotherapy among Medicaid-enrolled patients diagnosed with regional colon cancer.
  • Initial therapy with transarterial chemoembolization (TACE) versus Yttrium 90 radioembolization (Y 90 ) for hepatocellular carcinoma (HCC).
  • The addition of taxanes to adjuvant chemotherapy for lymph node positive (N+) early breast cancer (BC): Institutional practice variation in the National Comprehensive Cancer Network (NCCN)
  • The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada.
L1D876

(1.7)		T58 (30%): index_date (3%), claim (3%), gap (2%), real_world (2%), icd-9 (2%)

T51 (5%): mm (16%)

T312 (4%): 2l (14%), line (14%), nd_line (8%), lines (8%), 1st_line (8%)

T93 (4%): therapies (18%), 1l (15%)

T341 (2%): database (40%), diagnosis (27%)

T252 (2%): tx (25%), mos (16%)

T210 (2%): start (30%), initiation (27%), receiving (19%)

T238 (2%): patterns (63%)
  • Retrospective claims analysis of patient factors affecting multi-line treatment patterns in multiple myeloma (MM).
  • Characteristics and treatment patterns in patients newly diagnosed with chronic lymphocytic leukemia (CLL).
  • DTIC and GM-CSF in the treatment of patients with metastatic melanoma.
  • Treatment patterns in patients with early and advanced malignant melanoma.
  • Healthcare costs among multiple myeloma (MM) patients (Pts) without stem cell transplant (SCT).